Companion Diagnostics
Companion Diagnostics is a regulatory and clinical biomarker-based diagnostic strategy that identifies patients most likely to benefit from a specific therapeutic product, thereby enabling targeted therapeutic decision-making in precision medicine.
72
Publications
2.1K
Citations
301
Authors
128
Institutions
Publications per year
2017–2026
23
72
Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib
Joshua Bauml, Bob T. Li, Vamsidhar Velcheti et al. · Lung Cancer · 2021 · 69 citations · Full text
1–5 of 72
301
6
h-index
3
h-index
3
h-index
United States Food and Drug Administration, United States
3 publications · 312 citations
3
h-index
3
h-index
1–5 of 301
128
Center for Devices and Radiological Health
Rockville, United States
5 h-index
13 publications
1K citations
Yale University
New Haven, United States
4 h-index
6 publications
111 citations
United States Food and Drug Administration
Silver Spring, United States
4 h-index
12 publications
688 citations
The University of Texas MD Anderson Cancer Center
Houston, United States
4 h-index
17 publications
1.4K citations
DXC Technology (United States)
Tysons Corner, United States
4 h-index
4 publications
164 citations
Memorial Sloan Kettering Cancer Center
New York, United States
3 h-index
4 publications
181 citations
AstraZeneca (United Kingdom)
Cambridge, United Kingdom
3 h-index
4 publications
78 citations
National Cancer Institute
Bethesda, United States
3 h-index
19 publications
1.5K citations
1–8 of 128
10 publications · 615 citations
10
h-index
4 publications · 94 citations
4
h-index
3 publications · 67 citations
3
h-index
2 publications · 27 citations
2
h-index
2 publications · 24 citations
2
h-index
1–5